stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) EBITDA
Viking Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$402.1M, compared with −$167.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$652.8M. Over the past ten years it has ranged from −$402.1M (fiscal 2025) to −$11.0M (fiscal 2015) — the current reading is the lowest in ten years. EBITDA has fallen for 10 consecutive fiscal years. Viking Therapeutics, Inc. ranks 586th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$402.1M | — |
| FY2024 | −$167.7M | — |
| FY2023 | −$108.6M | — |
| FY2022 | −$68.8M | — |
| FY2021 | −$51.5M | — |
| FY2020 | −$38.5M | — |
| FY2019 | −$31.7M | — |
| FY2018 | −$24.9M | — |
| FY2017 | −$16.1M | — |
| FY2016 | −$11.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$187.8M | — |
| Jun 2026 | −$133.3M | — |
| Mar 2026 | −$165.3M | — |
| Dec 2025 | −$166.4M | — |
| 43 more quarters | Free account |
Against its own ten years
Low −$402.1M
High −$11.0M
Ten-year median
−$38.5M
Current reading's percentile
9
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| ELVN Enliven Therapeutics, Inc. compare | −$123.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| CELC Celcuity, Inc. compare | −$204.0M |
| IRON Disc Medicine, Inc. compare | −$273.8M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. | −$652.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item